Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, “Phreesia Inc. provides a patient intake management platform. The company’s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. “
Several other research firms also recently weighed in on PHR. Wells Fargo & Co assumed coverage on shares of Phreesia in a report on Monday, August 12th. They issued an outperform rating and a $23.00 price objective for the company. ValuEngine downgraded shares of Phreesia from a buy rating to a hold rating in a report on Thursday, October 31st. Robert W. Baird assumed coverage on shares of Phreesia in a report on Thursday, October 10th. They issued an outperform rating and a $31.00 price objective for the company. Chardan Capital assumed coverage on shares of Phreesia in a report on Tuesday, July 23rd. They issued a buy rating and a $33.00 price objective for the company. Finally, Piper Jaffray Companies set a $33.00 price objective on shares of Phreesia and gave the stock a buy rating in a report on Tuesday, September 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $30.60.
Shares of PHR traded down $0.26 during midday trading on Thursday, hitting $29.70. 119,587 shares of the stock traded hands, compared to its average volume of 272,714. Phreesia has a 1-year low of $22.05 and a 1-year high of $31.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.52 and a current ratio of 3.52. The company’s 50 day simple moving average is $27.07.
Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, September 9th. The company reported ($10.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($10.30). The firm had revenue of $30.82 million for the quarter, compared to the consensus estimate of $30.05 million. Analysts predict that Phreesia will post -0.56 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of PHR. Russell Investments Group Ltd. acquired a new stake in Phreesia in the 3rd quarter valued at about $47,000. Tower Research Capital LLC TRC acquired a new stake in Phreesia in the 3rd quarter valued at about $68,000. Rhumbline Advisers acquired a new stake in Phreesia in the 3rd quarter valued at about $208,000. Dean Capital Investments Management LLC acquired a new stake in Phreesia in the 3rd quarter valued at about $580,000. Finally, Emerald Advisers LLC acquired a new stake in Phreesia in the 3rd quarter valued at about $1,036,000. 0.03% of the stock is owned by institutional investors.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Recommended Story: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com